Clinical Trials Browser

Recruiting × Glioblastoma × Fluorodeoxyglucose F18 × Clear all

NCT06815029 2025-06-26

Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma

Phase 1 Recruiting

Astrocytoma, Glioblastoma, Lymphoma, Follicular